
<p><strong>&lt;&lt;insert slide 1 (00:00) chapter title:  Introduction   &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;</strong> <strong>Practical Considerations to Extend Treatment for VTE: What Every Clinician Needs to Know </strong></p>

<p><strong>&lt;&lt;insert slide 2  (00:20) chapter title:     &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Panelists</strong></p>

<p><strong>&lt;&lt;insert slide 3 (00:49) chapter title:     &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;VTE: Acute, Long-Term, and Extended Treatment<sup>[1]</sup></strong></p>

<p>&#8226;	The acute phase is the first week after VTE event, and it is the most dangerous time for patients, with the highest risk of death </p>

<p>&#8226;	The long-term phase is out to the 3-month point, during which data show that all patients require treatment</p>

<p>&#8226;	At the 3-month point, the extended treatment phase, a number of factors come into play, which determine who requires treatment beyond this point</p>

<p><strong>&lt;&lt;insert slide 4 (01:57) chapter title:  Provoked VTE   &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;Provoked VTE<sup>[2,3]</sup></strong></p>

<p>&#8226;	It is challenging to identify the patients who warrant extended treatment</p>



<p><strong>&lt;&lt;insert slide 5  (02:57) chapter title:  Unprovoked VTE   &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;Unprovoked VTE<sup>[4,5]</sup></strong></p>

<p>&#8226;	What we have learned is that patients with unprovoked VTE also have a considerable risk of recurrence</p>

<p>&#8226;	For many clinicians, it is not a driver that prompts continued extended prophylaxis, but in clinical practice, many of these patients have several factors that need to be taken into account</p>

<p>&#8226;	For these patients, it is much more a challenge to assess the risk of recurrence and to consider extended secondary VTE prevention</p>

<p><strong>&lt;&lt;insert slide 6 (05:14) chapter title: Effect of Gender   &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Men Are at Higher Risk of VTE Than Are Women <sup>[6,7]</sup></strong></p>



<p><strong>&lt;&lt;insert slide 7 (05:39) chapter title:  HERDOO2 Rule   &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; HERDOO2 Rule<sup>[2]</sup></strong></p>

<p>&#8226;	The HERDOO2 rule selects a lower-risk group of women who will not need extended anticoagulation because their risk of recurrence is 3% or less</p>

<p>&#8226;	Patients at a lower risk of recurrence are patients whose D-dimer is negative at the end of 3 or 6 months of anticoagulation and remains negative on serial testing</p>

<p><strong>&lt;&lt;insert slide 8 (07:02) chapter title:  VTE Extension Trials  &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;  VTE Extension Trials: NOACs vs Placebo<sup>[8-10]</sup></strong></p>

<p>&#8226;	Risk of recurrence is lower regardless of the non-vitamin K antagonist oral anticoagulant (NOAC) vs placebo </p>

<p>&#8226;	What is most important is that, even compared with placebo, the bleeding risk is no different with NOACs</p>

<p><strong>&lt;&lt;insert slide 9 (07:43) chapter title:   &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;  Extending Anticoagulation<sup>[11]</sup></strong></p>

<p>&#8226;	In the past, patients were not protected due to fear of bleeding and managing VKAs </p>

<p>&#8226;	NOACs are more convenient and provide safer anticoagulation, so the threshold for protecting patients against recurrent VTE has significantly decreased</p>

<p>&#8226;	The patient's initial presentation, whether it is a pulmonary embolism (PE) or a deep venous thromboembolism (DVT), is a factor to be taken into account when deciding on extending treatment</p>

<p>&#8226;	PEs are more likely to recur as PE, and the case-fatality rate of recurrent PE is higher than the potential hazards because of recurrent DVT<sup>[12]</sup></p>



<p><strong>&lt;&lt;insert slide 10 (10:15) chapter title:   &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;Bleeding<sup>[13]</sup></strong></p>

<p>&#8226;	EINSTEIN CHOICE demonstrated the ability to modulate intensity of treatment for the extended treatment phase and is a useful tool for clinicians<sup>[14]</sup></p>

<p><strong>&lt;&lt;insert slide 11  (12:32) chapter title: Aspirin     &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;Aspirin: WARFASA and INSPIRE<sup>[15,16]</sup></strong></p>



<p><strong>&lt;&lt;insert slide 12 (13:11) chapter title: EINSTEIN CHOICE    &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;EINSTEIN CHOICE: Study Design<sup>[14]</sup></strong></p>

<p>&#8226;	Patients who received standard anticoagulation for 6 to 12 months were then randomized to 1 of 3 groups: aspirin 100 mg, rivaroxaban 10 mg once daily, or rivaroxaban 20 mg once daily</p>

<p><strong>&lt;&lt;insert slide 13 (13:35) chapter title:     &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;EINSTEIN CHOICE: Primary Outcome -- Recurrent VTE<sup>[14]</sup></strong></p>

<p>&#8226;	Both doses of rivaroxaban were superior to low-dose aspirin</p>

<p>&#8226;	Low-dose aspirin was not as effective as anticipated</p>



<p><strong>&lt;&lt;insert slide 14 (14:22) chapter title:     &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;EINSTEIN CHOICE: Bleeding Outcomes<sup>[14]</sup></strong></p>

<p>&#8226;	There were similar rates of major bleeding among the 3 groups</p>

<p>&#8226;	Rivaroxaban 20 mg is associated with a slightly increased risk of nonmajor bleeds, whereas there was no difference between the 10 mg dose and low-dose aspirin</p>

<p>&#8226;	EINSTEIN CHOICE provides evidence for using the option of rivaroxaban 10 mg for secondary VTE prevention</p>

<p><strong>&lt;&lt;insert slide 15  (15:17) chapter title:     &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; EINSTEIN CHOICE: Provoked, Unprovoked, and History of VTE<sup>[14]</sup></strong></p>

<p>&#8226;	Subgroup analyses showed that these effects were consistent regardless of whether the patient had a provoked VTE, an unprovoked VTE, or a recurrent VTE</p>

<p>&#8226;	Bleeding risks remain similar among the groups</p>

<p>&#8226;	Aspirin may be an option only for patients who cannot afford NOACs</p>

<p> </p>

<p><strong>&lt;&lt;insert slide 16 (16:05) chapter title: AMPLIFY-EXT   &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; AMPLIFY-EXT<sup>[8]</sup></strong></p>

<p>&#8226;	There is a consistency across the class of factor Xa inhibitors</p>

<p><strong>&lt;&lt;insert slide 17 (16:59) chapter title: Use in Cancer   &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;NOACs in Prevention of Cancer-Associated VTE<sup>[17,18]</sup></strong></p>

<p><strong>&lt;&lt;insert slide 18 (19:02) chapter title: Adherence   &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;Adherence<sup>[19]</sup></strong></p>

<p><strong>&lt;&lt;insert slide 19 (20:18) chapter title:    &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;Timing of Doses</strong></p>



<p><strong>&lt;&lt;insert slide 20 (22:15) chapter title:  &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Anticoagulation and Need for Antiplatelet Therapy<sup>[15,20,21]</sup></strong></p>

<p>&#8226;	Very high-risk patients with the clear indication to continue anticoagulation were not included In EINSTEIN CHOICE and AMPLIFY-EXT</p>

<p><strong>&lt;&lt;insert slide 21 (24:04) chapter title:     &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;Summary</strong></p>

<p><strong>&lt;&lt;insert slide 22 (24:58) chapter title:     &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;Thank You</strong></p>



<p>&lt;&lt;end slides&gt;&gt;</p>

<p><em>This content has been condensed for improved clarity.</em></p>

